Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer
Osteoporosis, Prostate Cancer
About this trial
This is an interventional supportive care trial for Osteoporosis focused on measuring stage I prostate cancer, stage IIB prostate cancer, stage IIA prostate cancer, stage III prostate cancer, stage IV prostate cancer, osteoporosis
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed prostate cancer Stratum 1 (androgen ablation therapy): Bone metastases Prior orchiectomy allowed Prior or concurrent leuprolide and/or goserelin therapy allowed Stratum 2 (androgen ablation therapy): No bone metastases Prior orchiectomy allowed Prior or concurrent leuprolide and/or goserelin therapy allowed Stratum 3 (no androgen ablation therapy): No metastatic disease Prior flutamide or bicalutamide therapy allowed PATIENT CHARACTERISTICS: Age: Not specified Performance status: Not specified Life expectancy: Not specified Hematopoietic: Calcium normal Hepatic: Not specified Renal: Not specified PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics Endocrine therapy: See Disease Characteristics No concurrent high dose steroids Radiotherapy: Prior radiotherapy allowed Surgery: See Disease Characteristics Prior radical prostatectomy allowed Other: No concurrent bisphosphonates
Sites / Locations
- James P. Wilmot Cancer Center